AstraZeneca plc (ADR) Rating Lowered to Market Perform at Leerink Swann (AZN)
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated a “neutral” rating on shares of AstraZeneca plc (ADR) in a research note on Thursday. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc (ADR) in a research note on Wednesday, May 14th. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc (ADR) in a research note on Monday, May 12th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $64.50.
Shares of AstraZeneca plc (NYSE:AZN) opened at 80.28 on Monday. AstraZeneca plc has a 1-year low of $46.87 and a 1-year high of $82.68. The stock’s 50-day moving average is $71.03 and its 200-day moving average is $63.36. The company has a market cap of $101.2 billion and a price-to-earnings ratio of 49.37. AstraZeneca plc (ADR) also saw unusually large options trading activity on Friday. Investors purchased 18,875 put options on the stock. This is an increase of approximately 143% compared to the typical daily volume of 7,762 put options.
AstraZeneca plc (ADR) (NYSE:AZN) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.17 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter in the prior year, the company posted $1.41 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. Analysts expect that AstraZeneca plc will post $4.23 EPS for the current fiscal year.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.